

# CONTENTS

---

## KEY MESSAGES FROM THIS REPORT

### SUMMARY

### INTRODUCTION AND OBJECTIVE

### METHODOLOGY

*Response Rate*

*Analyses*

## SECTION 1: INTERNATIONAL PHARMACEUTICAL R&D EXPENDITURE AND SALES

1. Methodology
1. Figures
1. Definitions
- 1.1 R&D expenditure of respondent companies in 1996 and 1997e
- 1.2 R&D expenditure per company in 1996 and 1997e
- 1.3 Global changes in R&D expenditure between 1996 and 1997e
- 1.4 Percentage change in R&D expenditure 1996-1997e
- 1.5 Breakdown of R&D expenditure in 1996 by activity
- 1.6 Percentage of R&D expenditure in 1996 allocated to NASs
- 1.7 Growth in R&D expenditure of twenty respondents (1990-1997e)
- 1.8 Pharmaceutical sales of respondent companies in 1996 and 1997e
- 1.9 Pharmaceutical sales per company in 1996 and 1997e
- 1.10 Global changes in sales between 1996 and 1997e
- 1.11 Percentage change in sales 1996-1997e
- 1.12 Percentage of global sales in 1996 attributable to "top 3" products
- 1.13 Percentage of global sales in 1996 attributable to ethical pharmaceuticals first marketed in the previous five years
- 1.14 Growth in sales of twenty respondent companies (1990-1997e)
- 1.15 Ratio of R&D expenditure to sales in 1996 and 1997e
- 1.16 Ratio of R&D expenditure to sales for Leading companies and the rest of the pharmaceutical industry (1990-1996)
- 1.17 Discussion

*Continued...*

# CONTENTS

---

*...continued from previous page*

## **SECTION 2: PRODUCTS IN THE PIPELINE**

- 2. Methodology
- 2. Figures
- 2. Definitions
  - 2.1 Number of NASs in development per company
  - 2.2 Number of NASs in each clinical development phase on 31<sup>st</sup> December 1996
  - 2.3 NMEs in development by 11 Leading companies on 31<sup>st</sup> December 1995 and 31<sup>st</sup> December 1996
  - 2.4 Percentage of NASs in each clinical development phase
  - 2.5 Number of NASs in the clinical development pipeline by therapeutic area
  - 2.6 Top five therapeutic areas by number of NASs in development
  - 2.7 Number of companies active in each therapeutic area
  - 2.8 Therapeutic areas in which most and fewest companies are active
  - 2.9 Therapeutic distribution of NMEs marketed in the last decade and those in development
  - 2.10 Origin of NASs within the clinical development pipeline
  - 2.11 Analysis of biotech NASs in development on 31<sup>st</sup> December 1996
  - 2.12 Development stage in 1996 of those NMEs in development by 11 Leading companies in 1995
  - 2.13 Discussion

## **SECTION 3: NEW ACTIVE SUBSTANCE SUBMISSION, AUTHORISATION AND MARKETING ACTIVITY**

- 3. Methodology
- 3. Figures
- 3. Definitions
  - 3.1 Number of regulatory submissions for marketing within the EU and six other major markets in 1996
  - 3.2 Number of marketing authorisations within the EU and six other major markets in 1996

*Continued...*

# CONTENTS

---

*...continued from previous page*

- 3.3 Number of NASs launched within the EU and six other major markets in 1996
- 3.4 Time for the submission of an NME to achieve international status in 1996
- 3.5 Number of NASs launched onto their first market in the world in 1996 and 1997e
- 3.6 Number of NMEs marketed for the first time in the world (1987-1997e)
- 3.7 Development times for NMEs launched onto their first market in the world (1992-1996)
- 3.8 Discussion

## **CONCLUSION: SURVEY ON 1996 ACTIVITIES**

### **SECTION 4: REPORT ON OUTCOME OF CMR INTERNATIONAL INDUSTRY DISCUSSION MEETING**

#### **FUTURE WORK**

#### **ACKNOWLEDGEMENT**

#### **REFERENCES**

- APPENDIX 1** : Pharmaceutical companies invited to participate 1
- APPENDIX 2** : *International Pharmaceutical R&D Expenditure and Sales* questionnaire 1
- APPENDIX 3** : *Products in the pipeline* questionnaire 1
- APPENDIX 4** : *New active substance: submission, authorisation and marketing activity* questionnaire 1
- APPENDIX 5** : OECD mean exchange rates 1
- APPENDIX 6** : New molecular entities first launched on to the world market in 1996 1